phase readout
saveNCT02642042: Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
ACTIVE_NOT_RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
view source ↗
comments(0)
5-min edit window · permanent after that